Page 25 - Read Online

Page 10 of 10 Fowler et al. Hepatoma Res 2020;6:19 I http://dx.doi.org/10.20517/2394-5079.2020.21

display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010;51:2020-2029.
27. Wildner D, Bernatik T, Greis C, Seitz K, Neurath MF, et al. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular
carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med 2015;36:132-9.
28. Bhayana D, Kim TK, Jang HJ, Burns PN, Wilson SR. Hypervascular liver masses on contrast-enhanced ultrasound: the importance of
washout. AJR Am J Roentgenol 2010;194:977-83.
29. Han J, Liu Y, Han F, Li Q, Yan C, et al. The degree of contrast washout on contrast-enhanced ultrasound in distinguishing intrahepatic
cholangiocarcinoma from hepatocellular carcinoma. Ultrasound Med Biol 2015;41:3088-95.
30. Li R, Yuan MX, Ma KS, Li XW, Tang CL, et al. Detailed analysis of temporal features on contrast enhanced ultrasound may help
differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis. PLoS One 2014;9:e98612.
31. Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with
histologic differentiation. Radiology 2007;244:898-906.
32. Jang HJ, Kim TK, Burns PN, Wilson SR. CEUS: an essential component in a multimodality approach to small nodules in patients at high-
risk for hepatocellular carcinoma. Eur J Radiol 2015;84:1623-35.
33. Wilson SR, Kim TK, Jang HJ, Burns PN. Enhancement patterns of focal liver masses: discordance between contrast-enhanced
sonography and contrast-enhanced CT and MRI. AJR Am J Roentgenol 2007;189:W7-12.
34. Wilson SR, Lyshchik A, Piscaglia F, Cosgrove D, Jang HJ, et al. CEUS LI-RADS: algorithm, implementation, and key differences from
CT/MRI. Abdom Radiol (NY) 2018;43:127-42.
35. Lyshchik A, Kono Y, Dietrich CF, Jang HJ, Kim TK, et al. Contrast-enhanced ultrasound of the liver: technical and lexicon
recommendations from the ACR CEUS LI-RADS working group. Abdom Radiol (NY) 2018;43:861-79.
36. Kim TK, Noh SY, Wilson SR, Kono Y, Piscaglia F, et al. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system
(LI-RADS) 2017 - a review of important differences compared to the CT/MRI system. Clin Mol Hepatol 2017;23:280-9.
37. Yang HK, Burns PN, Jang HJ, Kono Y, Khalili K, et al. Contrast-enhanced ultrasound approach to the diagnosis of focal liver lesions: the
importance of washout. Ultrasonography 2019;38:289-301.
38. Terzi E, Iavarone M, Pompili M, Veronese L, Cabibbo G, et al. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in
cirrhosis in a multicenter restropective study of 1,006 nodules. J Hepatol 2018;68:485-92.
39. Li F, Li Q, Liu Y, Han J, Zheng W, et al. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with
and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version
2017. Eur Radiol 2020;30:461-70.
40. Chen LD, Ruan SM, Liang JY, Yang Z, Shen SL, et al. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma
in high-risk patients: A predictive model using contrast-enhanced ultrasound. World J Gastroenterol 2018;24:3786-98.
41. Chen LD, Ruan SM, Lin Y, Liang JY, Shen SL, et al. Comparison between M-score and LR-M in the reporting system of contrast-
enhanced ultrasound LI-RADS. Eur Radiol 2019;29:4249-57.
42. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, Gouw A, et al. cHCC-CCA: Consensus terminology for primary liver
carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology 2018;68:113-126.
43. Sciarra A, Park YN, Sempoux C. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma. Hum Pathol 2020;96:48-55.
44. Jung DH, Hwang S, Song GW, Ahn CS, Moon DB, et al. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma
following liver transplantation and resection. Liver Transpl 2017;23:330-41.
45. Potretzke TA, Tan BR, Doyle MB, Brunt EM, Heiken JP, et al. Imaging features of biphenotypic primary liver carcinoma
(Hepatocholangiocarcinoma) and the potential to mimic hepatocellular carcinoma: LI-RADS analysis of CT and MRI features in 61
Cases. AJR Am J Roentgenol 2016;207:25-31.
46. Wells ML, Venkatesh SK, Chandan VS, Fidler JL, Fletcher JG, et al. Biphenotypic hepatic tumors: imaging findings and review of
literature. Abdom Imaging 2015;40:2293-305.
47. Li F, Han J, Han F, Wang JW, Luo RZ, et al. Combined hepatocellular cholangiocarcinoma (Biphenotypic) tumors: potential role of
contrast-enhanced ultrasound in diagnosis. AJR Am J Roentgenol 2017;209:767-74.
48. Zheng W, Li Q, Zou XB, Wang JW, Han F, et al. Evaluation of Contrast-enhanced US LI-RADS version 2017: application on 2020 liver
nodules in patients with hepatitis B infection. Radiology 2020;294:299-307.
49. Abdel Razek AAK, El-Serougy LG, Saleh GA, Abd El-Wahab R, Shabana W. Interobserver agreement of magnetic resonance imaging of
liver imaging reporting and data system version 2018. J Comput Assist Tomogr 2020;44:118-23.